Document is current
Any future updates will be listed below
-
Authors
Khan, Mohid S. https://orcid.org/0000-0002-1272-241X
Cook, Kathryn
Weickert, Martin O. https://orcid.org/0000-0002-4070-8164
Davies, Louise
Pritchard, D. Mark https://orcid.org/0000-0001-7971-3561
Day, Melissa
Shah, Tahir https://orcid.org/0000-0002-0420-0304
Hull, Diana https://orcid.org/0000-0002-0425-541X
Caplin, Martyn https://orcid.org/0000-0003-0177-1352
Back, Melissa https://orcid.org/0009-0007-4430-6289
Pommie, Christelle https://orcid.org/0009-0001-8771-2304
Higgs, Kate
-
Funding
Funding for this research was provided by:
Ipsen Fund
- License Information
-
More Information
Article History
Received: 15 September 2023
Accepted: 12 February 2024
First Online: 29 February 2024
Declarations
:
: The study was performed in accordance with the recommendations of the Declaration of Helsinki and the guidelines for Good Pharmacoepidemiology Practices from the International Society for Pharmacoepidemiology. It also adhered to all local regulatory requirements applicable to non-interventional studies. The study protocol and supporting documents were submitted for National Health Service (NHS) Research Ethics Committee (REC) review via the Health Research Authority for the five UK sites. Research and development departments at participating sites issued capacity and capability statements, as a confirmation of approval, before patient recruitment commenced at the sites (REC reference: 21/ES/0021; IRAS project ID: 286528).
: Inclusion criteria for participants included that patients were willing and able to complete the study questionnaires in the quantitative online survey and willing and able to complete the one-to-one interview and be audio-recorded for the qualitative interviews.
: MB, KC, LD and DH have nothing to declare. MC: speaker fees and advisory board honorarium from Advanced Accelerator Applications (a Novartis company) and Ipsen MD: speaker fees and advisory board honorarium from Advanced Accelerator Applications (a Novartis company) and Ipsen. KH: Employee; Ipsen. MSK: speaker fees and advisory board honorarium from Advanced Accelerator Applications (a Novartis company), BMS, Ipsen and Novartis. CP: Employee; Ipsen. DMP: honoraria for consultancy and delivering presentations from Advanced Accelerator Applications (a Novartis company), INFAI, Ipsen and Mayoly Spindler Laboratories, and research funding to investigate the role of netazepide in gastric NETs from Trio Medicines Ltd. TS: research funding from Ipsen and Novartis, joint work projects for Advanced Accelerator Applications (a Novartis company) and Ipsen, and speaker honoraria from Advanced Accelerator Applications (a Novartis company) and Novartis. MOW: joint work projects and research funding from Novartis and Ipsen
: The authors thank Kirsty Walters (PhD) and Tamzin Gristwood (PhD) of Oxford PharmaGenesis, Oxford, UK, who provided medical writing and editorial support, which was sponsored by Ipsen in accordance with Good Publication Practice (GPP 2022) guidelines.
